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ABSTRACT
Pregnane X receptor (PXR), acting as a xenobiotic-
activated transcription factor, regulates the hepatic
metabolism of therapeutics as well as endobiotics
such as steroid hormones. Given our finding that
PXR activation by rifampicin (RIF) represses the
estrogen sulfotransferase (SULT1E1) gene in human
primary hepatocytes and hepatocellular carcinoma
Huh7 cells, here we have investigated the molecular
mechanism of this repression. First the PXR-
responsive enhancer was delineated to a 100bp
sequence ( 1000/ 901), which contains three half
sites that constitute the overlapping direct repeat
1 (DR1) and direct repeat 2 (DR2) motifs and two
forkhead factor binding sites. siRNA knockdown,
chromatin immunoprecipitation and chromatin con-
formation capture assays were employed to demon-
strate that hepatocyte nuclear factor 4a (HNF4a)
bound to the PXR-responsive enhancer, and acti-
vated the enhancer by looping its position close to
the proximal promoter. Upon activation by RIF, PXR
indirectly interacted with the enhancer, decreasing
the interaction with HNF4a and dissolving the
looped SULT1E1 promoter with deacetylation of his-
tone 3. Removal of the DR sites from the enhancer
hampers the ability of HNF4a to loop the promoter
and that of PXR to repress the promoter activity.
Thus, PXR represses human SULT1E1, possibly
attenuating the inactivation of estrogen.
INTRODUCTION
Pregnane X receptor (PXR), an orphan member of the nu-
clear steroid/thyroid receptor super-family, was ﬁrst char-
acterized as an activator of transcription of the CYP3A4
gene in response to various drugs and steroid metabolites
(1). PXR has now been established as a key transcription
factor that induces the hepatic capacity for xenobiotic me-
tabolism and excretion by activating a group of genes that
encode xenobiotic-metabolizing enzymes and transporters.
In addition, PXR has recently been reported to regulate
p38 mitogen-activated protein kinase-mediated cell migra-
tion signals by activating the GADD45  gene (2). The
general mechanism underlying these activations is a
direct binding of PXR to the response enhancers of its
target genes. PXR has also been demonstrated to repress
transcription of hepatic genes such as PCK1, G6Pase
and CYP7A1, thereby regulating energy and cholesterol
homeostasis (3–5). The repression of these genes appears
to be regulated through interactions of PXR with other
transcription factors and co-activators such as FOXO1,
CREB and PGC1a, but not by direct DNA binding.
However, the molecular mechanism by which PXR
represses transcription remains elusive at the present time.
Utilizing human estrogen sulfotransferase (SULT1E1) gene
as a model, here we have investigated the molecular mech-
anism of PXR-mediated repression of gene expression.
Estrogen levels can be regulated by altering biosynthesis
by aromatase, metabolic inactivation by sulfotransferase
and re-activation by sulfatase. Although the actions of es-
trogen and the development of estrogen-related diseases
by effects on aromatase are well established, estrogen me-
tabolism is also involved in the regulation of estrogen
activity. SULT1E1 exhibits the highest afﬁnity for estro-
gens among known sulfotransferases and is the primary
enzyme responsible for sulfation of b-estradiol and es-
trone. SULT1E1 is expressed at low levels in the livers
of normal mice and is highly expressed in livers of dia-
betogenic db/db mice (6). Expression of SULT1E1 in
adipose tissue of transgenic female mice revealed that
SULT1E1 activity regulates fat and glucose homeostasis
(7). Sult1e1
 /  female mice were reported to develop pla-
cental thrombosis and spontaneous fetal loss (8).
High estrogen sulfatase (STS) activity has been detected
in tumor tissues of breast cancer patients and was
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women (9,10). Drugs and steroid hormones are known
to induce SULT1E1 in mouse liver via activation of
nuclear receptors such as constitutive active/androstane
receptor (CAR), liver X receptor and glucocorticoid
receptor (11–13).
In this present study, given that the SULT1E1 gene was
repressed by rifampicin (RIF) in human primary hepato-
cytes, we utilized human hepatocellular carcinoma Huh7
and HepG2 cells to investigate the molecular mechanism
of the PXR-mediated repression of the SULT1E1 gene.
First the repressive activity was delineated to a 100bp
distal enhancer within the SULT1E1 promoter.
Subsequently, chromatin immunoprecipitation (ChIP)
and chromatin conformation capture (3C) assays were em-
ployed to identify hepatocyte nuclear factor 4a (HNF4a)
and its binding site within the 100bp enhancer as the target
of PXR to repress the SULT1E1 gene. Here, we present
these experimental considerations to suggest a novel mech-
anism, in which a drug-activated PXR cross-talks with
HNF4a, disrupting an active chromatin structure, and
thereby repressing transcription of the SULT1E1 gene.
EXPERIMENTAL PROCEDURES
Materials
RIF, SR12813, cycloheximide (CHX), TCPOBOP, anti-
FLAG-M2 HRP-conjugated antibody and FLAG-M2
agarose were purchased from Sigma-Aldrich (St Louis,
MO, USA); CITCO from BioMol (Plymouth Meeting,
PA, USA); restriction endonucleases and DNA-modifying
enzymes from New England Biolabs, Inc. (Beverly, MA,
USA); antibody to human PXR from Perseus Proteomics
Inc. (Tokyo, Japan); mouse, goat and rabbit normal IgGs,
antibodies against HNF3b (M-20), HNF4a (H-171) and
b-actin (C4) from Santa Cruz Biotechnology (Santa Cruz,
CA, USA); anti-V5 HRP-conjugated antibody from
Invitrogen (Carlsbad, CA, USA); anti-H3K9K14ac
(06–599) from Millipore (Billerica, MA, USA);
[
32P]dATP from GE Healthcare (Piscataway, NJ, USA)
and [
35S]methionine from PerkinElmer (Waltham, MA,
USA). ON-TARGETplus SMART pool HNF4a
(catalog number L-003406-00-0005), HNF3b (catalog
number L-010089-00-0005), PGC1a (catalog number
L-005111-00-0005) and ON-TARGETplus siCONTROL
non-targeting pool (catalog number D-001810-10) were
purchased from Dharmacon Research (Lafayette, CO,
USA). All primers, oligonucleotides and real-time PCR
probes used for present experiments are listed in
Supplementary Table S1–S4.
Expression plasmids and adenovirus
In all vectors, the preﬁxes h and m in front of inserts
denote human and mouse, respectively. pCR3/hPXR,
pCR3/FLAGhPXR, pcDNA3.1/hHNF4a, XREM-3A4-
Luc, pCR3/mCART176V, pGL3/1.8 kbp-2B6-Luc, adeno-
hPXR and adeno-b-gal have been described previously
(4,14–16). cDNA encoding the full-length human
HNF3b was ampliﬁed with appropriate PCR primers
and cloned into pcDNA3.1/V5-His-TOPO (Invitrogen)
to yield pcDNA3.1/hHNF3b.
Cloning of human SULT1E1 promoter
The 5.3 and 1.1kb DNA fragments containing the
50-ﬂanking region of human SULT1E1 gene were amp-
liﬁed from human genomic DNA (Promega, Madison,
WI, USA) using appropriate pairs of PCR primers.
Ampliﬁed DNA fragments were cloned into KpnI/XhoI-
digested pGL3-Basic vector (Promega) to yield pGL3/5.3
kb-hSULT1E1 and pGL3/1.1 kb-hSULT1E1, respective-
ly. The 100-bp enhancer region was ampliﬁed from pGL3/
5.3 kb-hSULT1E1 using appropriate pairs of PCR
primers and cloned into KpnI/XhoI-digested
pGL3-Basic vector containing a 160bp thymidine kinase
promoter to yield pGL3/hSULT1E1enhancer-TK (17).
Each of the mutant promoter constructs was
produced by site-directed mutagenesis using appropri-
ate oligonucleotides. To construct Luc reporter constructs
for 3C assays, a double-stranded oligonucleotide 50-GAT
CACTAGCAAAATAGGCTGTCCCCAGA-30 encoding
RV primer 3 was inserted into the BglII-digested site of
each Luc reporter constructs, and then the original
sequence of RV primer 3 in the pGL3-Basic was deleted
by site-directed mutagenesis.
Cell culture, drug treatment, transfection and infection
Human hepatocellular carcinoma Huh7 cells were main-
tained in minimal essential medium (MEM) supplemented
with 10% FBS, 2mM L-glutamine, penicillin (100 U/ml)
and streptomycin (100mg/ml) in an atmosphere of 5%
CO2 at 37 C. For Luc reporter assays, Huh7 cells were
transiently transfected with Fireﬂy luciferase reporter con-
struct along with pCR3/hPXR or pCR3/mCART176V,
using FuGene 6 (Roche Applied sciences, Indianapolis,
IN, USA). pRL-TK (Promega) was co-transfected as con-
trol. The ﬁnal amounts of transfected DNAs were adjusted
to constant levels by adding pCR3 (Invitrogen) empty
vector. Twenty-four hours after transfection, the cells
were treated with a given drug in FBS-free MEM for an
additional 24h and luciferase reporter assays were per-
formed as previously described (3). For adenoviral infec-
tion, cells were cultured in MEM medium containing
adeno-b-gal or adeno-hPXR at a multiplicity of infection
of 10. After incubation for 30h, these cells were treated
with either RIF (10mM) or SR12813 (3mM) in FBS-free
MEM for a given time. For siRNA knockdown, trypsin-
ized cells were reverse transfected with siRNA (50pmol) in
MEM medium, using Lipofectamine 2000 (Invitrogen).
After incubation for 24h, culture medium was replaced
with FBS-free MEM and cells were incubated for another
16h. For real-time PCR, trypsinized Huh7 cells were
reverse transfected with pCR3 or pCR3/mCART176V
using FuGene6. After 30h, cells were treated with
TCPOBOP (250nM) for 24h. Human primary heptocytes
were kindly provided by Dr Stephen S. Ferguson (Life
Technologies Corporation, Durham, NC, USA).
Hepatocytes were treated with RIF (10mM) or CITCO
(250nM) in William’s E medium supplemented with
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Real-time PCR
Real-time PCR was performed using an ABI prism 7700
sequence detection system (Applied Biosystems, Foster
City, CA, USA). Assays-on-Demand probes (Applied
Biosystems) were used for PCR with the TaqMAN PCR
Master Mix (Applied Biosystems). To measure the expres-
sion of human STS and CYP7A1 genes, SYBR Green
PCR Master Mix (Applied Biosystems) was used with spe-
ciﬁc primers. The TaqMAN human b-actin probe
(Applied Biosystems) was used as an internal control.
Gel shift assays
cDNAs for hHNF4a and hHNF3b in pcDNA3.1-V5-
His-TOPO vector were in vitro translated using the
TNT-coupled reticulocyte lysate system (Promega) ac-
cording to the manufacture’s instructions. Gel shift assays
were performed as described previously (18). For compe-
tition or antibody supershift assays, unlabeled oligo-
nucleotide, normal IgG, anti-HNF4a or anti-HNF3b
antibodies was added 15min before adding radioactive
oligonucleotides.
GST pull-down assays
Recombinant GST and GST-fusion proteins of hPXR and
hHNF4a were expressed in Escherichia coli BL21 (DE3)
cells, and were puriﬁed through glutathione-Sepharose. A
series of cDNAs for hPXR deletions and hHNF4a in
pCR3 or pcDNA3.1-V5-His-TOPO vector were in vitro
translated in the presence of [
35S] methionine using a
TNT-coupled reticulocyte lysate system (Promega) accord-
ing to the manufacture’s instructions. GST pull-down assays
were carried out as described previously (19).
Figure 1. PXR represses the SULT1E1 gene in human primary hepatocytes and Huh7 cells. (A) Human primary hepatocytes were treated with RIF
for 24h in William’s E medium, from which total RNAs were prepared and subjected to real-time PCR. The levels of the SULT1E1, STS and
CYP3A4 mRNAs are expressed by taking those in the DMSO-treated cells as one. *P<0.05 (DMSO versus RIF). (B and C) After 30h infection
with adeno-b-gal or adeno-hPXR, cells were treated with RIF for indicated time in FBS-free MEM (B) or were pre-treated with CHX (10mg/ml) for
2h, and then co-treated with RIF for another 16h (C). Total RNAs were prepared at the indicated time points and subjected to real-time PCR. The
levels of the SULT1E1, STS and CYP3A4 mRNAs are expressed taking those in the DMSO-treated Huh7 cells infected with adeno-b-gal as one.
Bars represent the mean±SD. *P<0.05 (PXR+DMSO versus PXR+RIF).
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ChIP assays were performed using a ChIP assay kit
(Millipore) according to the manufacture’s instruction.
Thirty hours after infection with adenovirus or reverse
transfection, cells were treated with RIF in FBS-free
MEM for an another 2 or 6h, and then cross-linked by
adding formaldehyde [ﬁnal 1% (v/v)] for 10min at room
temperature. Cells were lysed in SDS lysis buffer contain-
ing protease inhibitor cocktail (Roche Applied Science)
and sonicated to shear chromatin to lengths between
200 and 600bp. After pre-clearing by shaking with
Protein A or G agarose/salmon sperm DNA, cell lysates
were incubated with 3mg of antibodies or normal IgG
at 4 C for 16h. After incubation with Protein A or G
Figure 2. PXR represses the SULT1E1 promoter via the 100bp distal enhancer. (A) Huh7 cells were transiently transfected with the pGL3-Basic,
pGL3/5.3 kb-hSULT1E1, pGL3/5.3 kb-hSULT1E1del 1.0  0.8 kb or XREM-CYP3A4-Luc reporter constructs along with pCR3 or pCR3/hPXR for
24h and then treated with RIF or DMSO for another 24h in FBS-free MEM. pRL-TK was also included in all transfections as a control. Relative
Luc activity was calculated by taking the activity of cells co-transfected with pCR3 and pGL3-Basic and treated with DMSO as one. *P<0.05
(PXR+DMSO versus PXR+RIF). (B) Schematic diagram of a distal enhancer of the SULT1E1 promoter. (C and D) Huh7 cells were transiently
transfected with the pGL3/5.3 kb-hSULT1E1 or its indicated mutant constructs along with pCR3 or pCR3/hPXR for 24h and then treated with RIF
or DMSO for another 24h in FBS-free MEM. pRL-TK was also included in all transfections as a control. Relative Luc activity was calculated by
taking the activity of cells co-transfected with pCR3 and pGL3/5.3 kb-hSULT1E1 and treated with DMSO as one. Bars represent the mean±SD.
*P<0.05 (PXR+DMSO versus PXR+RIF).
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collected by centrifugation. After de-crosslinking and
protease-digestion, the immunoprecipitated DNA was
puriﬁed by following the manufacture’s instructions com-
bined with the QIAquick PCR puriﬁcation kit (Qiagen).
The puriﬁed DNA was used as a template for semi-
quantitative and real-time PCRs with speciﬁc primers.
3C assays
3C assays were performed as previously described with
minor modiﬁcations (20,21). Thirty hours after infection
with adenovirus, Huh7 cells were treated with RIF in
FBS-free MEM for another 6h. For 3C assays with Luc
reporter constructs, trypsinized Huh7 cells were reverse
transfected with each construct, using FuGene 6.
Twenty-four hours after transfection, the culture medium
was replaced with FBS-free MEM and the cells were incu-
bated for another 2h. Cells were cross-linked by adding
formaldehyde [ﬁnal 1% (v/v)] for 10min at room tempera-
ture, and the reaction was stopped by adding glycine (ﬁnal
125mM). After washing with ice-cold PBS, cells were
incubated in a lysis buffer [10mM Tris, pH 7.5, 10mM
NaCl, 0.2% (v/v) NP-40] and protease inhibitor cocktail
on ice for 15min, followed by homogenization in a dounce
homogenizer. After centrifugation, nuclei were collected
as a pellet and suspended in restriction enzyme buffer 2
containing 0.3% (w/v) SDS. After incubation at 37 C for
1h, Triton X-100 was added to 1.8% (v/v) ﬁnal concen-
tration, followed by incubation for another 1h at 37 C.
Aliquots of 1.5 10
6 nuclei were incubated with 500U of
BstYI at 37 C for 16h. The enzyme reaction was term-
inated by adding SDS to 1.6% (v/v) and incubated for
20min at 65 C. The digestion efﬁciency was conﬁrmed by
gel electrophoresis on a 2.0%, agarose gel. An aliquot of
digested chromatin was diluted with T4 DNA ligase buffer
to 1% (v/v) ﬁnal concentration Triton X-100 and 2.5ng/ml
of DNA and incubated at 37 C for 1h. The DNAs were
ligated by using 1600 cohesive end units of T4 ligase for
4h at 16 C followed by 30min at room temperature.
Proteinase K, NaCl and EDTA were added to the ligation
mixture to ﬁnal concentrations of 40mg/ml, 0.2M and
1mM, respectively. These mixtures were incubated at
65 C to reverse cross-linking. After 16h incubation, mix-
tures were treated with RNase A at 37 C for 30min, and
the DNA was puriﬁed by phenol extraction and ethanol
precipitation. The puriﬁed DNAs were re-suspended in
water at 50ng/ml, and subjected to semi-quantitative and
real-time PCR of ligated and control fragments using
speciﬁc pairs of primers.
Immunoprecipitation assays
Trypsinized cells were reverse transfected with pCR3/
FLAGhPXR for 24h, and were subsequently treated
with 0.1% (v/v) DMSO or RIF for another 2h. Then,
cells were lysed in cold immunoprecipitation buffer [1%
(v/v) Triton X-100, 150mM NaCl, 10mM Tris, pH 7.4,
1mM EDTA, 1mM EGTA, 0.2mM sodium ortho-
vanadate, 0.2mM PMSF, 0.5% (v/v) NP-40 and 0.1%
(v/v) DMSO or 20mM RIF] containing phosphatase in-
hibitor cocktails 1 and 2 (Sigma-Aldrich) at 4 C for 25min,
and were centrifuged at 16000g for 15min to prepare whole
cell lysates. For co-immunoprecipitation assays, FLAG-M2
agarose was incubated with cell lysates at 4 C for 2h,
washed with immunoprecipitation buffer and subjected
Figure 3. HNF4a is a primary factor regulating the SULT1E1 gene. (A) Huh7 cells were reverse transfected with control, HNF4a or HNF3b
siRNAs for 24h and were subsequently incubated in FBS-free MEM for another 24h. From these cells, total RNAs and whole cell lysates were
prepared and subjected to real-time PCR for SULT1E1, HNF4a and HNF3b mRNAs and western blottings using anti-HNF4a, anti-HNF3b and
anti-Actin antibodies. mRNA levels of each gene were expressed by taking those in the Huh7 cells reverse transfected with control siRNA as one.
Bars represent the mean±SD. *P<0.05 (control siRNA versus HNF4a siRNA). **P<0.05 (control siRNA versus HNF3b siRNA). (B) Huh7 cells
were subjected to ChIP assays using normal IgG, anti-HNF4a antibody or anti-HNF3b antibody as described in ‘Experimental Procedures’ section.
From the immunoprecipitated DNA fragments, the enhancer and proximal promoter regions were ampliﬁed by PCR using primers speciﬁc for the
SULT1E1 enhancer and SULT1E1 promoter. A region of exon 7 of the SULT1E1 gene was also ampliﬁed as a negative control.
8396 Nucleic Acids Research, 2011,Vol.39, No. 19to Western blotting with anti-FLAG-M2 HRP-conjugated
antibody or anti-V5 HRP-conjugated antibody.
Statistical analysis
All data are presented as mean±SD. Analysis was per-
formed by using Student’s t-test. A statistical probability
of P<0.05 was considered signiﬁcant.
RESULTS
PXR repression of the human SULT1E1 gene
Real-time PCR, performed using RNAs prepared from
human primary hepatocytes treated for 24h with the
human PXR activator RIF, determined that SULT1E1
mRNA levels decreased to approximately one-third
of those in DMSO-treated hepatocytes after RIF treat-
ment, while STS mRNA showed no change (Figure 1A).
The CYP3A4 mRNA was greatly increased as expected.
Repression of the SULT1E1 gene by RIF was also
observed in human hepatocellular carcinoma Huh7 cells
in which PXR was ectopically expressed through infec-
tion of an adenovirus. RIF treatment decreased the
levels of SULT1E1 mRNA in a time-dependent manner
in Huh7 cells infected with adeno-hPXR, but not with
adeno-b-gal; the decrease began 6h after treatment and
continued to an  85% decrease after 16h (Figure 1B).
Levels of STS mRNA, on the other hand, were main-
tained in Huh7 cells even after RIF treatment
(Supplementary Figure S1A). These PXR-mediated ex-
pression patterns were conserved in HepG2 cells
(Supplementary Figure S1B). Compared to the rapid
increase in CYP3A4 mRNA, which began 2h after RIF
treatment and peaked at the 6h mark, the gradual and
slow decrease in SULT1E1 mRNA levels prompted us
to examine whether or not protein synthesis was involved
in this repression. Co-treatment with cycloheximide
that inhibits translation did not block this decrease of
SULT1E1 mRNA levels, thus indicating that protein
Figure 5. PXR disrupts the enhancer-proximal promoter loop of the
SULT1E1 gene. (A) A schematic representation of the 3C assay of the
SULT1E1 gene. Numbers indicates positions relative to the transcrip-
tional start site; arrows indicate positions of PCR primers. (B) After
cross-linking by CH2O treatment, nuclei were prepared from Huh7 cells
and subjected to 3C assays as described in ‘Experimental Procedures’
section. From puriﬁed DNAs, formation of the 3C ligated product was
detected by PCR ampliﬁcation using TP1 and TP2 primers. Control
product was also ampliﬁed using CP1 and CP2 primers to verify the
quantity and quality of the DNA. (C) Huh7 cells were infected with
adeno-b-gal or adeno-hPXR for 30h, treated with RIF or DMSO
(DM) for another 6h in FBS-free MEM and then subjected to 3C
assays as described in ‘Experimental Procedures’ section. From
puriﬁed DNAs, formation of the 3C ligated product was determined
by real-time PCR. Values were normalized by ampliﬁcation of control
product and expressed by taking those levels in cells infected with
adeno-b-gal as one. Bars represent the mean±SD. *P<0.05
(b-gal+RIF versus PXR+RIF); **P<0.05 (PXR+DMSO versus
PXR+RIF).
Figure 4. Both the enhancer and proximal promoter are required for
the response to PXR. Huh7 cells were transiently transfected with the
pGL3-Basic, pGL3/1.1 kb-hSULT1E1 or pGL3/1.1 kb-hSULT1E1
along with pCR3 or pCR3/hPXR for 24h and then treated with RIF
or DMSO for another 24h in FBS-free MEM. pRL-TK was also
included in all transfections as a control. Relative Luc activity was
calculated by taking the activity of cells co-transfected with pCR3
and pGL3-basic as one. Bars represent the mean±SD. *P<0.05
(PXR+DMSO versus PXR+RIF).
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of the SULT1E1 gene (Figure 1C). Similarly, cyclohexi-
mide did not inhibit RIF induction of the CYP3A4
mRNA.
The PXR response enhancer within the SULT1E1 gene
First, we found that the 5.3kb SULT1E1 promoter-Luc
reporter was repressed  50% by RIF treatment in PXR-
expressing Huh7 cells (Figure 2A). Given the fact that
the internal deletion ( 1.0/ 0.8kb) abolished this
repression (Figure 2A), further deletion analysis deline-
ated the PXR-mediated repression activity to a distal
100bp composite enhancer sequence ( 1000/ 901bp)
(Figure 2B). This enhancer sequence contains three
direct repeat (DR) half sites that constitute the overlapp-
ing DR1 and DR2 motifs and two forkhead protein bind-
ing sites FHa and FHb. To determine the role of these half
sites, they were mutated singularly or simultaneously
within the context of the 5.3kb SULT1E1 promoter.
Mutation of DRb (DRb-mt) decreased activity of the
promoter and eliminated its ability to respond to PXR,
thereby repressing activity of the reporter (Figure 2C).
While single mutation of either DRa or DRc fully retained
PXR-mediated repression of the promoter, double muta-
tions of both DRa and DRc abolished this repression.
Thus, these results indicate that the DRb plays a central
role in the repression of the promoter activity. FHa and
FHb sites were also mutated to examine their role in re-
pression of activity of the 5.3kb SULT1E1 promoter; only
the double mutation abolished the response of the
promoter to PXR (Figure 2D). Taken together, these
results lead us to conclude that it is the DRb site
that plays the most critical role in the PXR-mediated
repression of the the 5.3kb SULT1E1 promoter,
although the two FH sites may also be involved in this
repression.
Roles of HNF4a and HNF3b in regulation of the
100bp enhancer
Subsequent to the conﬁrmation by gel shift assays that
HNF4a and HNF3b bind to the DR and FH sites, re-
spectively (Supplementary Figure S2), we employed
siRNAs to knockdown HNF4a and HNF3b in order to
examine their roles in regulating the SULT1E1 gene in
Huh7 cells. Both knockdowns were found to decrease
SULT1E1 mRNA levels (Figure 3A). Knockdown of
HNF4a was the most effective in decreasing SULT1E1
mRNA, and reduced the mRNA levels by 90%. On the
other hand, knockdown of HNF3b only reduced levels of
SULT1E1 mRNA by  40%. The HNF3b knockdown
also resulted in a small reduction of HNF4a, which is
consistent with the fact that HNF3b is one of the tran-
scription factors that activates the HNF4  gene (22).
To examine interactions of the 100bp enhancer with
HNF4a and HNF3b, ChIP assays were performed for
the SULT1E1 gene in Huh7 cells. Both HNF4a and
HNF3b bound to the enhancer region of the SULT1E1
promoter, but not to the proximal promoter region
(Figure 3B). These results indicate that HNF4a may
play the most critical role in enhancer activation,
although HNF3b is also involved in this activation.
Figure 6. PXR induces histone deacetylation of the SULT1E1 gene in Huh7 cells. Huh7 cells were infected with adeno-b-gal or adeno-hPXR for 30h
and treated with RIF or DMSO (DM) for additional 6h in FBS-free MEM. ChIP assays were performed with normal IgG or an anti-H3K9K14ac
antibody using both semi-quantitative PCR (A) and real-time PCR (B). Values are normalized by ampliﬁcation in sample inputs and expressed by
taking those in the DMSO-treated Huh7 cells infected with adeno-b-gal as one. Bars represent the mean±SD. *P<0.05 (b-gal+RIF versus
PXR+RIF); **P<0.05 (PXR+DMSO versus PXR+RIF).
8398 Nucleic Acids Research, 2011,Vol.39, No. 19Disruption of the chromatin structure
Utilizing deletion promoters, the regions required for re-
pression of activity by PXR were localized in the
SULT1E1 promoter. The activity of a  1.1kb promoter
was repressed by PXR, while a  1.1kb- promoter,
which places the enhancer in front of a 105bp proximal
promoter via an internal deletion, greatly enhanced the
basal transcription activity and fully retained the repres-
sion of activity by PXR (Figure 4). However, the 100bp
enhancer repressed promoter activity when it was placed
directly in the front of the TK promoter. Thus, the repres-
sive activity was minimized to the 100bp enhancer and the
 105bp proximal promoters (Supplementary Figure S3).
Noticing that the  1.1kb- promoter exhibited higher
activity than the  1.1kb promoter, we hypothesized that
the SULT1E1 promoter adopts a looped structure in its ac-
tive conformation. Utilizing the restriction enzyme BstYI
to digest the SULT1E1 gene, 3C assays were designed to
detect a 135bp DNA fragment by PCR ampliﬁcation
upon ligation of the BstYI sites that are located  1832bp
and+39bp from the transcriptional start site (Figure 5A).
Accordingly, this 3C assay demonstrated that the promoter
was looped in its active conformation (Figure 5B). The
same 3C assays were performed on the SULT1E1 gene
in PXR-expressing Huh7 cells after RIF treatment; amp-
liﬁcation of a 135bp DNA fragment was detected by both
semi-quantitative and real-time PCR. The degree of amp-
liﬁcation was strongly attenuated in the presence of PXR
after RIF treatment (Figure 5C). Subsequently, ChIP
assays were employed on the SULT1E1 gene using an
antibody that detects acetylated histone 3 at lysine 9 and
lysine 14 (H3K9K14ac); acetylation of histone 3 is known
to facilitate activation of gene transcription. H3K9K14ac
was reduced on both the enhancer and proximal promoter
regions of the SULT1E1 gene in PXR-expressing Huh7
cells after RIF treatment (Figure 6A and B). Thus, the
PXR-dependent chromatin structure disruption as
observed in our 3C assays correlated with this
deacetylation of histone 3 on the SULT1E1 gene.
HNF4a as a key PXR target for repression of promoter
activity
Next, ChIP assays were performed to determine the inter-
actions of HNF4a, HNF3b and PXR with the SULT1E1
Figure 7. PXR prevents HNF4a and HNF3b from binding to the 100bp enhancer. Huh7 cells were infected with adeno-b-gal or adeno-hPXR for
30h, treated with RIF or DMSO (DM) for another 2h in FBS-free MEM and then subjected to ChIP assays using normal IgG, anti-HNF4a
antibody, anti-HNF3b antibody or anti-human PXR antibody. (A) From the immunoprecipitated DNA fragments, the SULT1E1 enhancer,
SULT1E1 promoter and SULT1E1-ex7 were ampliﬁed by PCR. The region containing the DR3 sequence in the CYP3A4 gene was also ampliﬁed
for CYP3A4-XREM as a positive control for PXR activity. (B) The relative enrichment of the SULT1E1 enhancer in the immunoprecipitated DNA
fragments with anti-HNF4a and anti-HNF3b antibodies was determined by real-time PCR. Values are normalized by ampliﬁcation in sample inputs
and expressed by taking those in the DMSO-treated Huh7 cells infected with adeno-b-gal as one. Bars represent the mean±SD. *P<0.05
(b-gal+RIF versus PXR+RIF); **P<0.05 (PXR+DMSO versus PXR+RIF).
Nucleic Acids Research, 2011,Vol.39, No. 19 8399promoter. Binding of both HNF4a and HNF3b to the en-
hancer was attenuated after RIF treatment in PXR-
expressing Huh7 cells; no such attenuation was observed
with control b-gal-expressing Huh7 cells (Figure 7A and B).
HNF4a and HNF3b were not detected on the proximal
promoter even after RIF treatment under our assay con-
ditions. There was no PXR binding to either the enhancer
or to the proximal promoter before or after RIF treatment
(Figure 7A). Thus, PXR appeared to decrease the binding
of HNF4a and HNF3b to the enhancer, repressing
SULT1E1 promoter activity. To further distinguish the
roles of HNF4a and HNF3b, plasmid-based 3C assays
were developed in which the 5.3kb SULT1E1 promoter
plasmid was transfected into Huh7 cells and used as
template. BstY1 digestion was designed to produce a
111bp DNA fragment when the promoter adopted a
loop structure (Figure 8A and B). Within the context of
the 5.3kb SULT1E1 promoter, either DRb or both FH
sites were mutated and these mutated promoters were sub-
jected to 3C assays. Mutation of the DRb disrupted the
loop structure of the promoter by  60%, whereas only
<10% was decreased after mutation of the FH sites
(Figure 8C). This weak contribution by FH sites to the
loop structure was consistent with the less effect of
HNF3b knockdown on the expression of SULT1E1 gene
(Figure 3A).
Co-immunoprecipitation assays demonstrated that
PXR formed a complex with HNF4a in Huh7 cells, and
that formation of this complex formation was increased
following RIF treatment (Figure 9A). No such increase
was observed with HNF3b. These results, therefore, lead
us to conclude that it is the HNF4a that plays the primary
role in adopting the SULT1E1 promoter in the active loop
formation, and that PXR targets HNF4a to disrupt this
loop.
DISCUSSION
Here, we have identiﬁed the upstream enhancer of the
SULT1E1 promoter that plays a crucial role in regulating
the activity of SULT1E1 transcription. HNF4a binds to
the enhancer and acts as a mediator that enables the
SULT1E1 promoter to form an active chromatin structure
by placing the enhancer close to the proximal promoter,
thereby determining the basal rate of transcription. Upon
activation by RIF, PXR, through its interactions with
HNF4a, prevents the promoter from forming the active
chromatin structure, thereby repressing transcription of
the SULT1E1 gene. PXR was previously reported to
repress the expression of the G6Pase and CYP7A1 genes
through its interactions with HNF4a and PGC1a (4,5,19).
However, PGC1a does not appear to be involved in the
repression of the SULT1E1 gene, since the transcription of
the SULT1E1 gene was not affected by siRNA
knockdown of PGC1a in Huh7 cells (Supplementary
Figure S4). The chromatin structure-mediated repression
mechanism for the SULT1E1 gene differs from the
previous PGC1a-dependent gene repression by PXR.
FOXO1, HNF3b and CREB were also suggested to be
PXR targets for the protein–protein interactions, which
repress the expression of the G6Pase, CPT1A and
HMGCS2 genes, the molecular mechanism for which
remains unclear (3,4,23). Thus, SULT1E1 appears to be
Figure 8. HNF4a determines the chromatin structure of the SULT1E1
promoter. (A) A schematic presentation of ‘plasmid’ 3C assay of the
SULT1E1 gene. Arrows indicate positions of PCR primers. (B) Huh7
cells were reverse transfected with pGL3-BasicVec3C or pGL3/5.3 kb-
hSULT1E1Vec3C for 24h and then treated with DMSO in FBS-free
MEM for another 2h. After cross-linking by CH2O treatment, nuclei
were prepared and subjected to ‘plasmid’ 3C assays as described in
‘Experimental Procedures’ section. From puriﬁed DNAs, formation
of 3C ligated product was detected by PCR ampliﬁcation using
VecTP1 and VecTP2 primers. Control product was also ampliﬁed
using VecCP1 and VecCP2 primers to verify the transfection efﬁciency
and quality of the DNAs. (C) Huh7 cells were reverse transfected with
pGL3/5.3 kb-hSULT1E1Vec3C, pGL3/5.3 kb-hSULT1E1DRbVec3C or
pGL3/5.3 kb-hSULT1E1FHa/bVec3C. The relative looping formation in
the puriﬁed DNAs was determined by real-time PCR. Values were
normalized by ampliﬁcation of control product and expressed by
taking those in cells transfected with pGL3/5.3 kb-hSULT1E1Vec3C as
one. Bars represent the mean±SD. *P<0.05 (5.3kb+ligation versus
DRb+ligation).
8400 Nucleic Acids Research, 2011,Vol.39, No. 19the ﬁrst gene whose repression by PXR is now understood
at the level of chromatin structure.
PXR interacted with HNF4a in response to RIF acti-
vation, suggesting that this interaction can be a critical
regulatory step within the underlying mechanism, by
which PXR represses the expression of the SULT1E1
gene. Gel Shift assays indicated that PXR does not directly
bind to any DNA sequence within the 100bp enhancer
(data not shown). Therefore, if in fact PXR interacted
with the 100bp enhancer, this interaction would have
occurred via protein–protein interactions. However, our
ChIP assays did not conﬁrm that PXR interacted with
either the enhancer or the proximal promoter of the
SULT1E1 gene in RIF-treated Huh7 cells. Several
reasons for this can be speculated, one of which is that
the interaction of PXR with HNF4a on the SULT1E1
gene is transient, so that ability of ChIP assay to detect
this transient interaction may be limited (Figure 9B).
Although GST pull-down assays determined that PXR
and HNF4a bind through their DNA binding domains,
gel shift assays found that PXR does not inhibit binding of
HNF4a to the overlapping DR1 and DR2 motifs within
the 100bp enhancer (Supplementary Figures S5 and S6).
Therefore, PXR does not appear to just simply prevent
the binding of HNF4a. In this respect, HNF4a activity
can be regulated by post-translational modiﬁcations such
as acetylation and phosphorylation within its DNA
binding domain and hinge region (24–26). PXR may
also utilize these phosphatases and deacetylases to repress
the HNF4a-mediated activation of the SULT1E1 gene,
which presents an interesting possibility for future inves-
tigations to decipher the details of this repression
mechanism.
The liver is an estrogen-targeted organ, although
whether or not hepatic estrogen metabolism critically regu-
lates liver function in an autocrine and or paracrine fash-
ion remains to be further explored. Estrogen receptor a
(ERa) KO mice developed hepatic insulin resistance by
up-regulating lipogenic enzymes in the liver (27). Protein
S is a major risk factor for developing thrombosis and the
liver is the site of its production. ERa activation is known
to repress the protein S gene in mouse liver (28). Estrogens
regulate hepatic bile acid synthesis and a sustained activa-
tion of ERa by 17a-ethynylestradiol produces hepato-
toxicity in mice (29). Utilizing Pxr
 /  mice, we recently
determined that PXR represses the hepatic Sult1e1 gene
during fasting (data not shown). CAR, a closely related
nuclear xenobiotic-activated receptor, was reported to ac-
tivate the SULT1E1 gene in mouse liver (11). In human
primary hepatocytes, on the other hand, drug activation
of CAR resulted in repression of the SULT1E1 gene (30)
(Supplementary Figure S7). Moreover, similar to PXR,
CAR repressed the 5.3kb SULT1E1 promoter and the ex-
pression of the endogenous SULT1E1 gene in Huh7 cells
(Supplementary Figure S8). In addition to SULT1E1,
PXR and CAR can also regulate the expression of enzymes
that metabolize estrogens, such as CYP3A4, following
activation by an overlapping group of xenobiotics and
Figure 9. PXR exhibits a ligand-dependent interaction with HNF4a.( A) Huh7 cells were reverse transfected with indicated expression plasmids for
30h and then treated with RIF or DMSO (DM) for another 2h in FBS-free MEM, from which whole cell extracts were prepared and subjected to
immunoprecipitation with FLAG-M2 agarose. Immunoprecipitated proteins were detected by western blotting with anti-FLAG-M2 HRP-conjugated
antibody or anti-V5 HRP-conjugated antibody. (B) Model of mechanism for the PXR-mediated repression of the SULT1E1 gene.
Nucleic Acids Research, 2011,Vol.39, No. 19 8401therapeutics. Thus, PXR and CAR may co-operate in re-
gulating hepatic levels of active estrogens, thereby affect-
ing the physiology and/or pathophysiology of human
liver.
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